Advanced Therapy Medicinal Product (ATMP) Manufacturing Market Size & Trends

Page 1

Advanced Therapy Medicinal Product (ATMP) Manufacturing Market Size & Trends

According to a new market research report published by Global Market Estimates, the Global Advanced Therapy Medicinal Product (ATMP) Manufacturing Market is projected to grow from USD 9.37 billion in 2022 to USD 22.48 billion at a CAGR value of 12.8% from 2022 to 2027. The growing investment in the development of novel gene therapy-based cancer treatments, the growing availability of cell therapy in the market, the growing investment in ATMP manufacturing, and technological advancements in commercial ATMP manufacturing are the major drivers of the advanced therapy medicinal product (ATMP) manufacturing market.

Browse 155 Market Data Tables and 133 Figures spread through 156 Pages and in-depth TOC on “Global Advanced Therapy Medicinal Product (ATMP) Manufacturing Market - Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/advanced-therapy-medicinal-product-atmpmanufacturing-market-3801

By Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), By Scale (Precommercial/R&D Scale Manufacturing, Commercial Scale Manufacturing), By Workflow (Cell Banking & Processing, Process Development, Fill & Finish Operations, Analytical & Quality Testing), By Region (North America, Asia Pacific, Central & South America, Europe, and the Middle East & Africa), End-User Landscape Analysis, Company Market Share Analysis, and Competitor Analysis

Key Market Insights   

As per the therapy type outlook, the gene therapy segment is expected to be the largest segment in the Advanced Therapy Medicinal Product (ATMP) Manufacturing market from 2022 to 2027 The Asia Pacific region is analyzed to be the fastest-growing segment in the market As per the scale outlook, the commercial-scale manufacturing segment is expected to be the fastestgrowing segment in the advanced therapy medicinal product (ATMP) manufacturing market from 2022 to 2027 North America (the United States, Canada, and Mexico) will have a dominant share in the global Advanced Therapy Medicinal Product (ATMP) Manufacturing market from 2022 to 2027


Thermofisher Scientific, Inc., Merck KGaA, Lonza, Catalent Inc., Takara Bio Inc., F.Hoffmann-La Roche Ltd, Wuxi Advanced Therapies, Novartis AG, Miltenyi Biotec, bluebird bio, Inc., Boehringer Ingelheim International GMBH, Gilead Sciences, Inc., ElevateBio, LLC, VGXI, Inc., Sangamo Therapeutics, Inc., Oxford Biomedica, Aldevron, LLC, Novasep, Yposkesi, REGENXBIO Inc., Orchard Therapeutics, BioMarin Pharmaceutical Inc., Avantor, Inc., Astellas Pharma Inc., and Kriya Therapeutics, among others, are the some of the key players in the advanced therapy medicinal product (ATMP) manufacturing market

Therapy Type Outlook (Revenue, USD Billion, 2022-2027) 

Cell Therapy

Gene Therapy

Tissue Engineered Product

Scale Outlook (Revenue, USD Billion, 2022-2027) 

Pre-commercial/R&D Scale Manufacturing

Commercial Scale Manufacturing

Workflow Outlook (Revenue, USD Billion, 2022-2027) 

Cell Banking & Processing

Process Development

Fill & Finish Operations

Analytical and Quality Testing

Others

Regional Outlook (Revenue, USD Billion, 2022-2027) North America  

The U.S. Canada


Mexico

Europe      

Germany UK France Spain Italy Rest of Europe

Asia Pacific      

China India Japan South Korea Australia Rest of APAC

Central & South America   

Brazil Argentina Rest of CSA

Middle East & Africa   

Saudi Arabia UAE Rest of MEA

Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com Phone Number: +1 6026667238


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.